AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
The Food and Drug Administration has issued a new warning for atomoxetine HCI concerning the potential for severe liver injury. The drug, indicated for the treatment of attention-deficit hyperactivity disorder in adults and children, has been available since 2002.
Two cases of severe liver injury were reported in a teenager and an adult who had taken atomoxetine (Strattera) for several months. Both recovered normal liver function after discontinuing the medication. The actual number of liver injury cases is unknown due to possible underreporting.
The new labeling will state that severe liver injury may progress to liver failure, which can result in death or the need for an organ transplant. An insert also will give list signs and symptoms of liver problems. Atomoxetine should be discontinued in patients who ...